阿斯利康AstraZeneca plc (AZN) 2017年年度报告「LSE」.pdf

1、What science can doAstraZeneca Annual Report and Form 20-F Information 2017We are a global,science-led biopharmaceutical business and in this Annual Report we report on the progress we made in 2017 in pushing the boundaries of science to deliver life-changing medicines.Important information for read

2、ers of this Annual ReportFor more information in relation to the inclusion of Reported performance,Core financial measures and constant exchange rate(CER)growth rates as used in this Annual Report,please see the Financial Review on page 66.DefinitionsThe Glossary and the Market definitions table fro

3、m page 235 are intended to provide a useful guide to terms and AstraZenecas definitions of markets,as well as to acronyms and abbreviations,used in this Annual Report.Use of termsIn this Annual Report,unless the context otherwise requires,AstraZeneca,the Group,we,us and our refer to AstraZeneca PLC

4、and its consolidated entities.Cautionary statement regarding forwardlooking statementsA cautionary statement regarding forward-looking statements and other essential information relating to this Annual Report can be found on page 240.Directors Report The following sections make up the Directors Repo

5、rt,which has been prepared in accordance with the requirements of the Companies Act 2006:Chairmans Statement Chief Executive Officers Review Business Review Therapy Area Review Financial Review:Financial risk management Corporate Governance:including the Audit Committee Report and Corporate Governan

6、ce Report Directors Responsibility Statement Development Pipeline Sustainability:supplementary information Shareholder Information Strategic Report The following sections make up the Strategic Report,which has been prepared in accordance with the requirements of the Companies Act 2006:AstraZeneca at